The Novo Nordisk Foundation is committing up to DKK1.8 billion (US$260 million) to establish a research and vaccine development initiative that aims to create new or improved vaccines for respiratory diseases, including tuberculosis (TB) and influenza.
Teva Pharmaceutical Industries Ltd. and Biolojic Design Ltd. have announced an exclusive license agreement to develop a potential novel antibody-based therapy for the treatment of atopic dermatitis and asthma.
Korro Bio Inc. has nominated its first development candidate, KRRO-110, for the potential treatment of α1-antitrypsin deficiency. KRRO-110 is a proprietary RNA editing oligonucleotide delivered to liver cells using clinically validated LNP technology licensed from Genevant.
Leukotriene B4 (LTB4) stimulates the release of cytokines and mediators that participate in tissue inflammation and acts as a chemoattractant for neutrophils, eosinophils and monocytes at the inflammation site.
Ethris GmbH has received approval from the U.K. Medicines and Healthcare products Regulatory Agency (MHRA) to proceed with a first-in-human trial of its inhaled mRNA program, ETH-47, in healthy participants for the treatment and prophylaxis of respiratory viral infections.
BMPR2 mutations are the most common genetic cause of pulmonary arterial hypertension (PAH). Pulmonary artery endothelial cells (PAECs) with reduced BMPR2 expression are linked to a persistent DNA damage after reoxygenation. Forkhead box F1 (FOXF1) is a transcription factor with affinity for endothelial cells in the lung, and its reduced expression has also been associated with DNA damage in those cells and PAH.
Chiesi Farmaceutici SpA has disclosed imidazole derivatives acting as TGF-β receptor type-1 (TGFBR1; ALK5; SKR4; TβR-I) inhibitors reported to be useful for the treatment of idiopathic pulmonary fibrosis (IPF).
Based on previous studies that have demonstrated the potential of growth hormone-releasing hormone receptor (GHRH-R) antagonists to modulate immune responses to bleomycin lung injury, researchers from the University of Miami and affiliated organizations aimed to evaluate the potential of the GHRH-R antagonist MIA-602 in a mouse model of rVSV-SARS-CoV-2-induced pulmonary dysfunction and heart injury.
ΔF508-CFTR is the most common CFTR mutation in cystic fibrosis (CF), which leads to destabilization of CFTR’s first nucleotide-binding domain (NBD1), contributing centrally to defective ΔF508-CFTR folding, trafficking and function.
Researchers from Arcturus Therapeutics Inc. and affiliated organizations presented preclinical data for LUNAR-CFTR, a novel mutation-agnostic, aerosolized CFTR replacement therapy for the treatment of cystic fibrosis (CF).